CONDENSED CONSOLIDATED STATEMENTS STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid‑in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balances (in shares) at Dec. 31, 2021		31,224,336
Beginning balances at Dec. 31, 2021	$ 298,718	$ 3	$ 392,384	$ 0	$ (93,669)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		24,891
Issuance of common stock upon exercise of stock options	50		50
Vesting of early exercised options (in shares)		15,224
Vesting of early exercised options	35		35
Stock-based compensation	1,794		1,794
Other comprehensive loss	(1,535)			(1,535)
Net loss	(21,671)				(21,671)
Ending balances (in shares) at Mar. 31, 2022		31,264,451
Ending balances at Mar. 31, 2022	277,391	$ 3	394,263	(1,535)	(115,340)
Beginning balances (in shares) at Dec. 31, 2021		31,224,336
Beginning balances at Dec. 31, 2021	$ 298,718	$ 3	392,384	0	(93,669)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of early exercised options (in shares)	53,741
Ending balances (in shares) at Dec. 31, 2022	31,394,767	31,394,767
Ending balances at Dec. 31, 2022	$ 212,554	$ 3	402,893	(2,057)	(188,285)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	18,344	18,344
Issuance of common stock upon exercise of stock options	$ 129		129
Vesting of early exercised options (in shares)	43,588	10,153
Vesting of early exercised options	$ 26		26
Vesting of restricted common stock (in shares)		91,859
Shares issued (in shares)		1,618,613
Issuance of common stock in connection with the Vertex Agreement	19,407		19,407
Stock-based compensation	2,755		2,755
Other comprehensive loss	1,415			1,415
Net loss	$ (6,674)				(6,674)
Ending balances (in shares) at Mar. 31, 2023	33,133,736	33,133,736
Ending balances at Mar. 31, 2023	$ 229,612	$ 3	$ 425,210	$ (642)	$ (194,959)